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Abstract
Background: Lipid accumulation in the liver and pancreas is primarily caused by combined hyperlipidemia. However,
the effect of isolated hypercholesterolemia without hypertriglyceridemia is not fully described. Therefore, our aim was
to investigate whether hypercholesterolemia alone leads to alterations both in hepatic and pancreatic lipid panel and
histology in rats.
Methods: Male Wistar rats were fed with 2% cholesterol +0.25% cholate-supplemented diet or standard chow for
12 weeks. Blood was collected at weeks 0, 4, 8 and 12 to measure serum cholesterol and triglyceride levels. At
week 12, both the pancreas and the liver were isolated for further histological and biochemical analysis. Hepatic
and plasma fatty acid composition was assessed by gas chromatography. Expression of mRNA of major enzymes
involved in saturated/unsaturated fatty acid synthesis was analyzed by qPCR. In separate experiments serum enzyme
activities and insulin levels were measured at week 9.
Results: At week 12, rats fed with 2% cholesterol +0.25% cholate-supplemented diet were characterized by elevated
serum cholesterol (4.09 ± 0.20 vs. 2.89 ± 0.22 mmol/L, *p < 0.05) while triglyceride (2.27 ± 0.05 vs. 2.03 ± 0.03 mmol/L)
and glucose levels (5.32 ± 0.14 vs. 5.23 ± 0.10 mmol/L) remained unchanged. Isolated hypercholesterolemia increased
hepatic lipid accumulation, hepatic cholesterol (5.86 ± 0.22 vs. 1.60 ± 0.15 ng/g tissue, *p < 0.05) and triglyceride contents
(19.28 ± 1.42 vs. 6.78 ± 0.71 ng/g tissue, *p < 0.05), and hepatic nitrotyrosine level (4.07 ± 0.52 vs. 2.59 ± 0.
31 ng/mg protein, *p < 0.05). The histology and tissue lipid content of the pancreas was not affected. Serum total protein
level, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities remained unchanged in response to
isolated hypercholesterolemia while serum alkaline phosphatase activity (ALP) significantly increased. Plasma insulin levels
did not change in response to isolated hypercholesterolemia suggesting an intact endocrine function of the pancreas.
Isolated hypercholesterolemia caused a significantly increased hepatic and serum fatty acid level associated
with a marked alteration of fatty acid composition. Hepatic expression of Δ9-desaturase (SCD1) was increased
4.92×, while expression of Δ5-desaturase and Δ6-desaturase were decreased (0.447× and 0.577×, respectively)
due to isolated hypercholesterolemia.
Conclusions: Isolated hypercholesterolemia leads to hepatic steatosis and marked alterations in the hepatic lipid profile
without affecting the pancreas. Altered fatty acid profile might mediate harmful effects of cholesterol in the liver.
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Stearoyl-coenzyme a desaturase (SCD), Lipotoxicity, Lipid droplets
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Background
Hyperlipidemia has been shown to affect morphology,
metabolism, and biological functions of several organs
including e.g. the liver [1, 2], pancreas [2–4], heart [5–9],
vasculature [10], skeletal muscle [11], etc. Based on the key
lipid component [i.e. triglyceride and/or cholesterol], hyper-
lipidemia could be classified into three types: (i) isolated
hypertriglyceridemia, (ii) isolated hypercholesterolemia, and
(iii) combined hyperlipidemia (both hypertriglyceridemia
and hypercholesterolemia) [12].
In Western societies, combined hyperlipidemia could
be developed as a consequence of sedentary lifestyle,
dietary habits and obesity. Combined hyperlipidemia is
a common disease in the population aged 20 and over.
Its prevalence was 13.4% in the United States in 2009–2010
[13]. According to a Mexican survey, the simultaneous
elevation of cholesterol and triglyceride concentrations was
observed in 12.6% of the general population (cholesterol
concentration above 6.3 mmol/L [240 mg/dl]) [14]. Never-
theless, in this study, 3.5% of all individuals was found to
have isolated hypercholesterolemia [14].
It is well-established that clinically manifested combined
hyperlipidemia could induce severe fatty degeneration in
the hepatocytes termed non-alcoholic fatty liver disease
[15]. It may develop into non-alcoholic steatohepatitis in
20–30% of the cases [16] and potentially lead to hepatic
fibrosis [17]. Combined hyperlipidemia was found to in-
duce acute pancreatitis with characteristic histological al-
terations [18–20]. Furthermore, acute pancreatitis induced
by cerulein, taurocholate or L-arginine was suggested to
be aggravated in the presence of combined hyperlipidemia
[21, 22]. Other studies have mainly focused on the fatty
infiltration of the pancreas in response to hyperlipidemia
and obesity [23], however, these mostly epidemiological/
pathological reports did not indicate the type of hyperlipid-
emia. Nevertheless, experimental combined hyperlipidemia
has been shown to cause increased pancreatic triglyceride
accumulation in rats and mice as assessed by both bio-
chemical and histological tools [20, 24].
Interestingly, isolated hypercholesterolemia is less sur-
veyed in clinical studies. Therefore, mainly experimental
data demonstrated deterioration of normal liver architec-
ture, lipid infiltration and mild liver fibrosis in rats in re-
sponse to isolated hypercholesterolemia [25–27]. However,
to the best of our knowledge no study has been performed
to elucidate the effects of isolated hypercholesterolemia on
pancreatic tissue.
The majority of studies investigating the accumulation
of lipids in different organs have been focused either on
the liver or on the pancreas. In case of epidemiological
reports, the type of hyperlipidemia is not always clear.
Moreover, relatively few studies have examined the ef-
fects of certain types of hyperlipidemia both on the liver
and the pancreas in the same experimental setup. It has
been reported that combined hyperlipidemia caused an
increased amount of intracellular lipid droplets in the
liver, whereas the pancreas remained unchanged under
the same conditions [28, 29]. In contrast, both pancreatic
and hepatic triglyceride contents were higher in mice due
to combined hyperlipidemia in other studies [24, 30].
Nonetheless, the effects of isolated hypercholesterolemia
on the lipid content of the liver and the pancreas have not
been investigated in the same experimental setup.
Therefore, the aim of our study was to investigate whether
isolated hypercholesterolemia leads to simultaneous devel-
opment of steatosis in the liver and the pancreas. Therefore,
we investigated the morphology and major lipid panel (chol-
esterol and triglycerides) both of the liver and the pancreas
in a non-obese rat model of isolated hypercholesterolemia
(2% cholesterol +0.25% cholate-supplemented diet for
12 weeks without any extra triglyceride administration).
Methods
Animals and experimental protocol
The investigation conforms to the Guide for the Care
and Use of Laboratory Animals published by the U.S.
National Institutes of Health [National Institutes of Health
publication 85–23, revised 1996], and was approved by the
local animal ethics committee of the University of Szeged.
In order to induce isolated hypercholesterolemia, male
Wistar rats (130–164 g) were fed with laboratory chow
supplemented with 2% (w/w) cholesterol (Hungaropharma
Zrt., Budapest, Hungary) and 0.25% (w/w) sodium-cholate-
hydrate (Sigma, St. Louis, MO) for 12 weeks (Fig. 1a) as
described previously [31, 32]. Control rats were fed with
standard rat chow. Body weight and serum cholesterol, tri-
glyceride, and blood glucose levels were measured at weeks
0, 4, 8, and 12 (Fig. 1a). At the end of the diet period, the
liver and the pancreas were isolated from both groups in
order to perform histological analysis and to measure tissue
cholesterol and triglyceride levels. In addition, hepatic
nitro-oxidative stress was assessed by measuring tissue 3-
nitrotyrosine level, and characterization of fatty acid com-
position of the liver and plasma was performed by gas
chromatography.
Measurement of serum lipid and blood glucose levels
Blood samples were collected from the saphenous vein
after overnight fasting. Blood glucose level was immedi-
ately determined by a standard glucose meter in dupli-
cates (Accutrend GCT, Roche Diagnostics, Mannheim,
Germany) as described previously [33–36].
For serum lipid measurements, collected blood was
allowed to clot and then was centrifuged (2000 g, 15 min,
4 °C). Serum cholesterol and triglyceride levels were assayed
by enzymatic colorimetric assays (Cholesterol PAP and
Triglyceride PAP assays; Diagnosticum, Budapest, Hungary)
as described earlier [37, 38].
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Measurement of tissue lipid levels
Liver and pancreas samples were homogenized
(homogenization buffer: 20 mM TrisBase; 150 mM NaCl;
pH 7.8; 0.05% TritonX100) with a sonicator (4 °C; 3 × 10 s;
Hielscher UP100H Ultrasonic Processor [Hielscher
Ultrasonics, Teltow, Germany]) and centrifuged (1000 g;
5 min; 4 °C). Tissue cholesterol and triglyceride were mea-
sured from the supernatant by enzymatic colorimetric
assays according to the manufacturer’s instructions
(CHOD-PAP and GPO-PAP assays; Cobas-Roche, West
Sussex, England).
Measurement of serum enzyme activities and plasma
insulin levels
In separate experiments blood samples were collected
from the aorta after overnight fasting in a group of male
Wistar rats fed with normal or 2% (w/w) cholesterol and
0.25% (w/w) sodium cholate hydrate supplemented stand-
ard chow for 9 weeks.
Serum liver enzyme activities including alanine amino-
transferase (ALT), aspartate aminotransferase (AST) and
alkaline phosphatase (ALP) as well as plasma total protein
concentration were measured to monitor the effect of
cholesterol and cholic acid enriched diet on liver function.
Serum ALT, AST and ALP activities were measured with
test kits from Roche Diagnostics (Mannheim, Germany)
on Roche Modular P800 chemistry analyzer. Plasma total
protein concentration were determined by a bicinchoninic
acid protein assay kit (Pierce, BCA protein assay kit) in
triplicates according to the manufacturer’s instructions.
Serum pancreatic enzyme activities including amylase and
lipase were measured to determine the effect of cholesterol
plus cholic acid enriched diet on the exocrine pancreas
function. Serum amylase (EPS-G7 substrate) and lipase ac-
tivities were measured with test kits from Diagnosticum
(Budapest, Hungary) and Roche Diagnostics (Mannheim,
Germany), respectively on Roche Modular P800 chemistry
analyzer.
To monitor the effect of cholesterol and cholic acid
enriched diet on the endocrine pancreas, plasma insu-
lin levels were measured by an enzyme immunoassay
(Mercodia, Ultrasensitive Rat Insulin ELISA) in dupli-
cates according to the manufacturer’s instructions as
described previously [33–36].
Histology
Samples from the liver and the pancreas tail were fixed
overnight in 4% (v/v) neutral formaldehyde solution and
embedded in paraffin. Four μm tissue slices were sub-
jected to hematoxylin-eosin (liver, pancreas), toluidine
blue (liver), and Crossman’s trichrome (liver) staining.
The histology was scored by the method described pre-
viously [39, 40] with minor modifications by an expert
pathologist in a blinded manner. In case of the liver, 6
different signs: (i) xanthomatous alterations, (ii) steatotic
microvesicles, (iii) portal fibrosis, (iv) hyperplasia of
Kuppfer cells, (v) biliary cell proliferation and (vi) lobu-
lar inflammation; in case of the pancreas 5 different
signs: (i) vacuolization, (ii) fatty infiltration, (iii) relative
number of islets, (iv) islet deformations and (v) hemosid-
erin content were graded from 0 to 3, respectively. In
this scale 0 = absent, 1 = mild, 2 = moderate and
3 = severe representation of histological signs. The
total alteration was calculated by summarizing the scores
for the different parameters.
Fatty acid analysis
Plasma samples (2.5–4 mL) were saponified using
2.5 mL of 18.6 mol/L NaOH and 40 mL of methanol.
Nonadecanoic acid (0.7 mg) was used as an internal
standard (1 g/L in chloroform/isopropanol (1:2, v/v).
Fig. 1 a Experimental protocol; b Body weight of control (o) and
isolated hypercholesterolemic (●) rats in week 0, 4, 8, and 12; c liver
weight index (liver weight/body weight) and d pancreas weight
index (pancreas weight/body weight) at the end of the diet. Data
are mean ± SEM, n = 12, respectively, *p < 0.05 vs. control
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The solution was heated in 80 °C for 50 min, and samples
were acidified with citric acid, extracted with chloroform
and methylated with methanol and methanolic-boron-
trifluoride. Liver samples (1200 mg) were prepared as de-
scribed above by using 5 mg of internal standard. Fatty
acid methyl esters were separated by gas-liquid chroma-
tography on a Shimadzu 2010 chromatograph (Shimadzu
Corporation, Tokyo, Japan) fitted with automatic sampler
AOC-20 and FID detector. The used column was a CP Sil
88 fused capillary column (50 m × 0.25 mm × 0.20 μm
film thickness). Helium was used as carrier and make-
up gas. The split ratio was 50:1. The injection port
temperature was set to 270 °C and the detector was
300 °C. Oven temperature was increased from 80 °C to
205 °C by 1.7 °C/min, held for 5 min then increased to
225 °C by 10 °C/min, held for 20 min. Individual fatty
acids were identified by comparison of gas chromatog-
raphy peaks with peaks of known standards (Mixture Me
100, Larodan Fine Chemicals AB, Limhamn, Sweden).
Fatty acid composition was expressed as μg fatty acid per
g liver or plasma wet weight.
Measurement of hepatic 3-nitrotyrosine level
To further characterize hepatic damage induced by isolated
hypercholesterolemia 3-nitrotyrosine level was measured in
liver samples as a marker of tissue nitro-oxidative stress
using ELISA (Cayman Chemical, Ann Arbor, MI, USA) as
described previously [38, 41, 42]. Briefly, homogenates were
incubated overnight with nitrotyrosine acetylcholinesterase
tracer and anti-nitrotyrosine rabbit IgG in microplates pre-
coated with mouse anti-rabbit IgG. Ellman’s reagent was
used for development.
Total RNA isolation and quantitative polymerase chain
reaction [qPCR]
Total RNA was isolated from 22 to 30 mg homogenized
tissue with RNeasy Fibrous Tissue Mini kit (QIAGEN,
Austin, Texas, USA) as described by the manufacturer.
DNA was degraded with TURBO™ DNase (Ambion, Life
Technologies, Carlsbad, California, USA). RNA concen-
tration was measured with NanoDrop1000 Version 3.8.1.
(Thermo Fisher Scientific Inc., Waltham, MA, USA). cDNA
synthesis was performed with High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems Foster City, CA,
USA) and cDNA was diluted 4× for PCR.
qPCR reaction was performed with Rotor-Gene Version
6.0 (Corbett Research, Sydney, Australia). Mastermix was
prepared from 5 μL FastStart Essential DNA Green Master
(Roche Applied Science, Mannheim, Germany) and 0.5 μL
primer solution (10 pM) for one sample and 4.5 μL cDNA
was added. The following PCR protocol was applied: heat-
start at 95 °C for 10 min; 45 cycles of 95 °C for 15 s; 60 °C
for 10 s and 72 °C for 20 s. Tm values were compared and
non-template controls were run to verify the specificity of
the primers. The sequences of the primers are pre-
sented in Table 1. Gene expression was normalized to
HPRT1 and PPIA.
Statistical analysis
Data were expressed as means ± standard error of the
mean (SEM). Serum enzyme activities (ALT, AST, ALP,
amylase, lipase) and plasma total protein as well as insu-
lin levels, liver and pancreas cholesterol and triglyceride
content, hepatic nitro-tyrosine as well as individual fatty
acid contents were analyzed with Student t-test. Body
weight, serum cholesterol and triglyceride levels were
analyzed by repeated measures ANOVA followed by
Dunn’s post hoc test. Histological scores were analyzed
by Mann-Whitney U test. qPCR results were evaluated
by Welch’s test. P < 0.05 was accepted as statistically sig-
nificant difference.
Results
Animal and organ weights
Body weight was not affected significantly in the hyper-
cholesterolemic group compared to the control group
(Fig. 1b). In order to compare individual cases properly,
organ weights were indexed by body weights. Liver
weight index significantly increased in the hypercholes-
terolemic group (Fig. 1c); however, there was no signifi-
cant difference in terms of pancreas index between
control and hypercholesterolemic groups (Fig. 1d).
Serum cholesterol, triglyceride and blood glucose
To validate the development of isolated hypercholesterol-
emia, cholesterol and triglyceride concentrations were mea-
sured in the serum of the animals. Elevation of serum
cholesterol concentration was observed due to cholesterol-
supplemented diet on weeks 4, 8 and 12 (Fig. 2a), while
serum triglyceride concentrations did not change in parallel
(Fig. 2b). Blood glucose levels were not different in the
hypercholesterolemic animals as compared to the control
animals (Fig. 2c).
Lipid content of the liver and the pancreas
To analyze the effect of isolated hypercholesterolemia
on tissue lipid content, hepatic and pancreatic choles-
terol and triglyceride content were assessed at the end of
the 12-weeks diet period. Hepatic cholesterol level was
significantly elevated in the hypercholesterolemic rats
(Fig. 3a), while pancreatic cholesterol level remained un-
affected (Fig. 3b). Similarly, hepatic triglyceride content
was significantly increased (Fig. 3c), but pancreatic tri-
glyceride content did not change in response to isolated
hypercholesterolemia (Fig. 3d).
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Serum enzyme activities and plasma insulin concentration
Isolated hypercholesterolemia significantly increased
serum ALP (Fig. 4c), while only induced a slight but not
significant increase in ALT and ASP activities (Fig. 4a
and b). Plasma total protein level did not change signifi-
cantly in response to isolated hypercholesterolemia as
compared to the normal group (57.08 ± 1.58 vs.
51.41 ± 2.58 g/L, respectively). To test the effect of
isolated hypercholesterolemia on the exocrine and endo-
crine pancreas function, serum lipase and amylase activity
as well as plasma insulin concentrations were determined
(Fig. 4d-f). Plasma amylase activity (a non-specific marker
for pancreas damage) showed significant increase in the
isolated hypercholesterolemic group (Fig. 4e), while lipase
activity (a specific marker for pancreas damage) did not
change. Plasma insulin concentrations were not different
between the two groups (Fig. 4f).
Histological analyses of the pancreas and the liver
Isolated hypercholesterolemia significantly altered the
histological picture of the liver according to hepatic hist-
ology score (Fig. 5a, c, and d; Table 2). Changes were
predominantly manifested in xanthomatous alterations
and steatotic microvesicles. In contrast, pancreatic hist-
ology was not modified by isolated hypercholesterolemia
in terms of gross morphological parameters as compared
with rats on control diet (Fig. 5b, e, and f; Table 2).
Nitro-oxidative stress in the liver
As we have not experienced any signs of pathological al-
terations in the pancreas, in the rest of the study we have
only focused on hepatic characterization. Since chronic
hyperlipidemia induces nitro-oxidative stress in various
organs, we have tested hepatic 3-nitrotyrosine levels. We
have found that 3-nitrotyrosine was increased significantly
due to isolated hypercholesterolemia (Fig. 6).
Fatty acid composition of the liver and the plasma
In order to further characterize the effects of isolated
hypercholesterolemia on tissue and serum lipid profile,
we have analyzed the fatty acid composition of the liver
and the plasma. Gas chromatographic analysis confirmed
that total hepatic fatty acid content was significantly
increased due to isolated hypercholesterolemia. In the
liver of control animals, the predominant fatty acids
were arachidonic (C20:4n-6), linoleic (C18:2n-6),
palmitic (C16:0), stearic (C18:0), oleic (C18:1n-9) and
docosahexaenoic acid (C22:6n-3, Table 3). In addition
to the previously listed fatty acids, palmitoleic acid
(C16:1n-7) also became a major component in the liver
of hypercholesterolemic rats.
Absolute amount of almost every measured fatty acid
was significantly increased in the liver due to isolated
hypercholesterolemia most significantly: palmitoleic
acid (C16:1n-7), oleic acid (C18:1n-9), eicosatrienic acid
(C20:3n-3), α-linolenic acid (C18:3n-3) and myristic
acid (C14:0). Nevertheless, the quantity of docosahexae-
noic acid (C22:6n-3) did not change significantly and
stearic acid (C18:0) and arachidonic acid (C20:4n-6)
were significantly decreased in the liver (Table 3).
In the plasma of control and hypercholesterolemic rats
the dominant fatty acids were the same as in the liver
(Table 4). The pattern of fold-change of individual fatty
acids due to cholesterol-enriched diet in the plasma was
Table 1 Sequence of the primers utilized in evaluation of fatty acid biosynthesis in livers of rats with isolated hypercholesterolemia
NCBI Reference Sequence Symbol Official full name Sequence
NM_139192.2 SCD1 Stearoyl-coenzyme A desaturase 1
[delta-9-desaturase]
Fw tgctctgagctgttttgttga
Rv cgaaggcatttccagagg
NM_031841.1 SCD2 Stearoyl-coenzyme A desaturase 2
[delta-9-desaturase]
Fw ggtgtcgatgggagctgt
Rv ttgatgtgccagcggtact
NM_053445.2
Transcript variant X1: XM_006231075.2
FADS1 Fatty acid desaturase 1 Fw gagggcattcatgcacaga
Rv aggcagacatggtcacacc
NM_031344.2
Transcript variant X1: XM_008760244.1
FADS2 Fatty acid desaturase 2 Fw agagaagccgctgctgag
Rv tgcttcatttgtggaggtagg
NM_017332.1 FASN Fatty acid synthase Fw ttcagagctacagaaggtgctaga
Rv tctaactggaagtgacggaagg
NM_012583.2 HPRT1 Hypoxanthine phosphoribosyltransferase 1 Fw gaccggttctgtcatgtcg
Rv acctggttcatcatcactaatcac
NM_017101.1 PPIA Peptidylprolyl isomerase A
[cyclophilin A]
Fw tctgcactgccaagactgag
Rv catgccttctttcaccttcc
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also similar to changes seen in the liver; however, the
degree was less pronounced.
mRNA expression of enzymes involved in fatty acid synthesis
We investigated the expression of mRNAs of major en-
zymes involved in the synthesis of saturated and unsat-
urated fatty acids (Figs. 7, 8 and 9), including fatty acid
synthase (FASN), stearoyl-coenzyme A desaturase 1
(Δ9-desaturase; SCD1), stearoyl-coenzyme A desaturase
2 (Δ9-desaturase; SCD2), fatty acid desaturase 1 (Δ5-
desaturase; FADS1) and fatty acid desaturase 2 (Δ6-
desaturase; FADS2). The expression of mRNAs of
FADS1 (Δ5-desaturase) and FADS2 (Δ6-desaturase) sig-
nificantly decreased in the liver due to isolated hyper-
cholesterolemia. In contrast, the expression of mRNA
of stearoyl-coenzyme A desaturase 1 (Δ9-desaturase, SCD1)
significantly increased in the liver of hypercholesterolemic
rats. However, the levels of FASN and SCD2 mRNAs did
not change significantly (Fig. 7).
Discussion
In the present, study we have investigated the effects of
isolated hypercholesterolemia both on hepatic and pan-
creatic lipid profile and histology. Here we have demon-
strated for the first time that a cholesterol-enriched diet
leading to the development of isolated hypercholesterol-
emia resulted in accumulation of not only cholesterol
but, interestingly, also triglyceride in the liver. Moreover,
increased nitro-oxidative stress and histological signs of
hepatic steatosis have also been developed in isolated
hypercholesterolemia. However, isolated hypercholester-
olemia did not cause any alterations in lipid levels or
gross histology in the pancreas in the same experimental
setup. In addition, we have found marked alterations in
the fatty acid composition of the liver as well as the
plasma in hypercholesterolemic rats due to changes in
the hepatic expression of SCD1, FADS1 and FADS2.
In developed countries, isolated hypercholesterolemia
may constitute a significant proportion of hyperlipidemia
with elevated cholesterol level in the adult population [1, 6].
In experimental studies, the development of hyperlipidemia
is influenced by a variety of factors including e.g. the type
of animals, diet duration, ingredients and their proportion,
etc. In our present study, we used a non-obese model of
isolated hypercholesterolemia characterized previously by
our [31, 32] and other research groups as well [18, 43]. In
agreement with these aforementioned studies, we have con-
firmed here that 2% cholesterol and 0.25% sodium-cholate-
hydrate enriched diet for 12 weeks leads to increased serum
cholesterol level, without affecting serum triglyceride level
in rats.
The major goal of our present study was to compare
the effects of isolated hypercholesterolemia both on lipid
content and histology of the liver and the pancreas in
the same experimental setup. Interestingly, the majority
of studies regarding the effects of hyperlipidemia have
been focused on either the liver or the pancreas. Thus,
in the present study we have demonstrated for the first
time in the literature that isolated hypercholesterolemia
causes marked cholesterol and also triglyceride accumu-
lation in the liver accompanied by steatotic degener-
ation, while the pancreas remains unaffected in the same
experimental setup. As there was no comparative study
conducted, we compared our results only with studies
looking at the effect of isolated hypercholesterolemia
either on the liver or on the pancreas.
Regarding the effects of isolated hypercholesterolemia
on the liver, our findings are in accordance with those of
Wang et al. [44], who observed that isolated hyperchol-
esterolemia [induced by a diet supplemented with 2%
Fig. 2 a Serum Cholesterol (n = 6–9); b serum triglyceride (n = 7–9);
and c serum blood glucose (n = 6–9) in control (o) and isolated
hypercholesterolemic (●) rats in week 0, 4, 8, and 12. Data are
mean ± SEM, *p < 0.05 vs. control
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b d
Fig. 3 Effect of isolated hypercholesterolemia on a pancreas tissue cholesterol, b liver tissue cholesterol; c pancreas tissue triglyceride; d liver
tissue triglyceride at the end of the diet. Data are mean ± SEM n = 10, respectively, *p < 0.05 vs. control
Fig. 4 Effect of isolated hypercholesterolemia on serum enzyme activities including a AST, b ALT, c ALP, d amylase, e lipase and f plasma insulin
concentration at week 9. Data are mean ± SEM n = 7–8, respectively, *p < 0.05 vs. control
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cholesterol and 0.5% cholic acid] increased liver weight
and also induced fatty degeneration of the liver in Wistar
rats. In our present study, isolated hypercholesterolemia
lead to slightly increased ALT and ASP activities and
induced a significant elevation of serum ALP activity.
Plasma total protein level did not change in response to
isolated hypercholesterolemia as compared to the normal
group. These results suggest that isolated hypercholester-
olemia leads to steatosis without severely affecting liver
function. Some other research groups using different diet
supplementation regimes have shown a more severe form
of hepatic injury, i.e. hepatic fibrosis due to isolated hyper-
cholesterolemia induced by a diet containing 2% choles-
terol, 5% olive oil and 0.5% cholic acid for 2 weeks in
Wistar rats [18, 20]. Our present findings confirm these
aforementioned studies showing that isolated hypercholes-
terolemia induces liver injury. Interestingly, the presence
of cholesterol in the diet is necessary for triglyceride accu-
mulation in the liver, as 5% dietary fat alone has no such
effect [45]. The mechanisms by which hypercholesterol-
emia lead to excessive alterations in lipid profile are not
clear. Gene regulatory effects of cholesterol are not fully
understood yet, however, mechanistic studies showed that
the sterol regulatory element-binding protein is a
membrane-bound protein which could be cleaved due to
hypercholesterolemia, and its intracellular remnant acts as
a transcription factor subsequently binding to the sterol
regulatory element sequence of DNA [46–48].
In analogy to the effects of isolated hypercholesterol-
emia on the liver, we presumed that isolated hyperchol-
esterolemia may induce morphological damages in the
pancreas as well. There are some reports showing that
combined hyperlipidemia has an exacerbating effect in
acute pancreatitis [21–25]. However, we could not reveal
any vacuolization of acinary cells or an increase in the
activity of serum lipase, a pancreas damage-specific
marker, induced by isolated hypercholesterolemia. Amyl-
ase activity was significantly increased in our study,
Fig. 5 Effect of isolated hypercholesterolemia on hepatic (a, n = 12) and pancreatic (b, n = 6) histology evaluated by a score system at the end
of the diet. Data are mean ± SEM, *p < 0.05 vs. control. Representative images of histological sections of the liver (c: Control, d: Chol, scale bars
represent 400 μm (top) or 100 μm (bottom) and pancreas (e: Control, f: Chol, scale bars represent 200 μm (top) or 50 μm (bottom) stained with
hematoxylin and eosin. Arrow shows intracellular lipid droplets in the liver
Table 2 Histological scores of the liver and pancreas of rats with isolated hypercholesterolemia
LIVER Xanthomatous
alteration
Steatotic
microvesicles
Portal fibrosis Kuppfer
hyperplasia
Biliary proliferation Lobular
inflammation
Control 0.00 ± 0.00 0.25 ± 0.13 0.08 ± 0.08 0.17 ± 0.11 0.17 ± 0.11 0.33 ± 0.19
Chol 2.17 ± 0.24 1.08 ± 0.08 0.00 ± 0.00 0.00 ± 0.00 0.08 ± 0.08 0.08 ± 0.08
Significance p < 0.05 p < 0.05 n.s. n.s. n.s. n.s.
PANCREAS Vacuolisation Fatty infiltration Relative number of islets Islet deformations Hemosiderin content of islets
Control 0.00 ± 0.00 0.00 ± 0.00 0.83 ± 0.40 1.00 ± 0.37 0.00 ± 0.00
Chol 0.17 ± 0.17 0.00 ± 0.00 0.67 ± 0.33 1.00 ± 0.52 0.00 ± 0.00
Significance n.s. n.s. n.s. n.s. n.s.
Control: standard diet; Chol: 2% cholesterol and 0.25% cholic acid enriched diet for 12 weeks; n = 6–12
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however, amylase is less specific for pancreas damage
and may have extrapancreatic origin. Interestingly high
fat diet increases both liver and salivary amylase activity
[49, 50]. Pancreatic steatosis has recently been investi-
gated in details. Systemic conditions, e.g. dyslipidemia,
obesity may lead to the development of fatty infiltration
of the pancreas as well as the liver [23, 24, 27]. Some
studies have reported that experimental combined hyperlip-
idemia causes increased triglyceride accumulation in the
pancreas and lipid droplets in acinary cells, i.e. pancreatic
steatosis in different animals [23, 27]. In contrast, triglycer-
ide accumulation and histological signs of pancreatic stea-
tosis failed to develop due to isolated hypercholesterolemia
in the present study. Therefore, one may speculate that
Fig. 6 Effect of isolated hypercholesterolemia on hepatic 3-nitrotyrosine level. Data are mean ± SEM, n = 8, *p < 0.05 was accepted significant
change vs. control (p < 0.05)
Table 3 Fatty acid content of the liver in isolated hypercholesterolemia
Control Chol
Code Name Average SEM Average SEM Fold change p value
C14:0 Myristic acid 85.0 4.85 476 35.7 5.60 2.68E-10 ↑↑
C15:0 Pentadecanoic acid 62.3 7.51 297 20.1 4.77 2.18E-10 ↑
C16:0 Palmitic acid 5817 146 12,437 568 2.14 1.28E-10 ↑
C16:1n-7 Palmitoleic acid 333 34.5 6768 695 20.28 5.00E-09 ↑↑↑
C17:0 Heptadecanoic acid 159 5.65 283 12.5 1.78 6.45E-09 ↑
C18:0 Stearic acid 4598 71.1 3218 65.1 0.70 1.25E-12 ↓
C18:1n-9 Oleic acid 3306 170 23,114 1385 6.99 1.50E-12 ↑↑
C18:2n-6 Linoleic acid 6246 353 18,903 776 3.03 6.10E-13 ↑
C18:3n-6 γ-Linolenic acid 75.8 7.63 201 21.5 2.66 1.46E-05 ↑
C18:3n-3 α-Linolenic acid 129 12.9 728 44.6 5.64 9.80E-12 ↑↑
C20:2n-6 Eicosadienoic acid 111 5.69 442 26.0 3.98 1.88E-11 ↑
C20:3n-3 Eicosatrienoic acid 118 11.8 777 52.2 6.55 2.39E-11 ↑↑
C20:4n-6 Arachidonic acid 6895 243 6143 130 0.89 0.0125 ↓
C20:5n-3 Eicosapentaenoic acid 73.0 6.97 197 10.7 2.71 1.85E-09 ↑
C22:5n-3 Docosapentaenoic acid 283 12.6 769 53.5 2.72 1.07E-08 ↑
C22:6n-3 Docosahexaenoic acid 1313 50.4 1452 106 1.11 0.2474 n.s.
Total fatty acid content 29,612 941 76,293 3386 2.58 5.55E-12
Control: standard diet; Chol: 2% cholesterol and 0.25% cholic acid enriched diet for 12 weeks. Fatty acid content is given in μg/g wet weight. n = 12
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elevation of plasma triglycerides is essential to the develop-
ment of acute pancreatitis and pancreatic steatosis.
The lack of obesity and the fact that there were no differ-
ences in plasma insulin and serum glucose and triglyceride
levels in our model suggest that isolated hypercholesterol-
emia does not lead to massive alterations in the endocrine
function of the pancreas. Although our study is limited in
this aspect as we have not specifically investigated this issue.
Tissue lipid accumulation is often associated with in-
creased nitro-oxidative stress in various organs, there-
fore we have also investigated the effect of isolated
hypercholesterolemia on nitro-oxidative stress in the
liver. Our findings showing elevated hepatic nitro-
oxidative stress due to isolated hypercholesterolemia is
in line with our own observations made previously in
the heart [32, 37, 42].
Table 4 Fatty acid content of the plasma in isolated hypercholesterolemia
Control Chol
Code Name Average SEM Average SEM Fold change p value
C14:0 Myristic acid 9.81 0.73 14.0 1.06 1.43 0.0036 ↑
C15:0 Pentadecanoic acid 7.69 0.49 14.0 1.18 1.82 0.0001 ↑
C16:0 Palmitic acid 455 27.9 521 35.4 1.15 0.1563 n.s.
C16:1n-7 Palmitoleic acid 35.7 5.80 195 29.6 5.46 2.68E-05 ↑↑
C17:0 Heptadecanoic acid 9.55 0.60 14.2 1.22 1.49 0.0024 ↑
C18:0 Stearic acid 199 9.56 148 11.3 0.74 0.0024 ↓
C18:1n-9 Oleic acid 305 27.3 707 69.6 2.32 2.05E-05 ↑
C18:2n-6 Linoleic acid 546 37.1 742 49.0 1.36 0.0041 ↑
C18:3n-6 γ-Linolenic acid 8.27 0.81 9.05 1.54 1.09 0.6588 n.s.
C18:3n-3 α-Linolenic acid 13.5 1.30 23.9 1.79 1.77 0.0001 ↑
C20:2n-6 Eicosadienoic acid 5.35 0.42 12.2 0.77 2.29 9.11E-08 ↑
C20:3n-3 Eicosatrienoic acid 6.25 0.84 26.0 2.02 4.16 7.31E-09 ↑↑
C20:4n-6 Arachidonic acid 607 31.2 477 35.6 0.78 0.0114 ↓
C20:5n-3 Eicosapentaenoic acid 12.4 1.24 11.5 1.28 0.93 0.6432 n.s.
C22:5n-3 Docosapentaenoic acid 16.5 1.35 18.6 1.66 1.13 0.3388 n.s.
C22:6n-3 Docosahexaenoic acid 61.1 3.70 59.9 6.55 0.98 0.8724 n.s.
Total fatty acid content 2304 130 3007 233 1.30 0.0153
Control: standard diet; Chol: 2% cholesterol and 0.25% cholic acid enriched diet for 12 weeks. Fatty acid content is given in μg/g plasma. n = 11–12
Fig. 7 Effect of isolated hypercholesterolemia on mRNA expression of major enzymes involved in the synthesis of saturated and unsaturated fatty
acids. Data are mean ± SEM, n = 8, *was accepted significant change vs. control (p < 0.01). FASN: fatty acid synthase, SCD: stearoyl-coenzyme A
desaturase (Δ9-desaturase), FADS1: fatty acid desaturase 1 (Δ5-desaturase), FADS2: fatty acid desaturase 2 (Δ6-desaturase)
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Since we revealed significant structural alterations
macroscopically and marked biochemical changes in the
overall lipid content of the liver, we next analyzed the
composition of this lipid accumulation by using gas
chromatography. Almost all fatty acids we examined
showed a significant elevation in the liver in response to
isolated hypercholesterolemia. The explanation for the
increased overall fatty acid level observed in isolated
hypercholesterolemia is not clear and should be investi-
gated in separate studies, since we have not found increased
FASN expression in our study. In contrast, amount of some
fatty acids, i.e. stearic acid (C18:0) and arachidonic acid
(C20:4n-6), showed a significant decrease. These results are
very similar to those reported by Muriana et al. in rats fed a
diet containing 10% olive oil or primrose oil with or with-
out 1% cholesterol showing no change in stearic acid and a
significant decrease in arachidonic acid due to cholesterol
supplementation [51]. Among all increased fatty acids the
monounsaturated ones (palmitoleic acid (C16:1n-7) and
oleic acid (C18:1n-9)) showed the most pronounced alter-
ation in our present study. A feasible explanation for these
findings could be an increase in hepatic SCD activity, since
SCD convert stearic acid and palmitic acid to oleic acid and
palmitoleic acid, respectively. Indeed, SCD1 activity was
significantly increased at the transcript level in the liver of
hypercholesterolemic rats, however, SCD2 activity failed to
increase at the transcript level in hypercholesteremic livers
in the present study (Fig. 7).
Palmitoleic acid (C16:1n-7) decreases the activity and
expression of LDL-receptors, therefore, elevates the serum
concentration of cholesterol [3]; whereas oleic acid (C18:1n-
9) and stearic acid (C18:0) act reversely [14]. Oleic acid
Fig. 8 Synthesis of the n-3 (ω-3) fatty acid family members
Fig. 9 Synthesis of the n-6 (ω-6) fatty acid family members
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(C18:1n-9) and stearic acid (C18:0), however, promotes the
fatty degeneration, i.e. steatosis, of hepatic cells in different
models [52–55]. Furthermore, palmitoleic acid (C16:1n-7)
especially, but other fatty acids as well, activate uncoupling
protein 2, which may lead to hepatic steatosis [56, 57].
In addition to monounsaturated fatty acids, most of the
polyunsaturated fatty acids [most significantly eicosatrienic
acid and α-linolenic acid] were also increased in the liver
due to isolated hypercholesterolemia (Table 3). Eicosatrie-
noic acid (C20:3n-3) was shown to be directly converted to
leukotrienes [58] which may play an important role in the
pathogenesis of hepatic steatosis.
The effects of decreased expression of both FADS1
and FADS2 were clearly visible in our present study as a
blockade in the polyunsaturated fatty acid (PUFA) syn-
thesis. The two independent families of PUFAs include
namely the n-3 (ω-3, Fig. 8) and n-6 (ω-6, Fig. 9) fatty
acids which changed in a similar manner. The amount
of the end products (docosahexaenoic acid in the n-3
and arachidonic acid in the n-6 family) did not show any
elevation in response to isolated hypercholesterolemia
due to decreased expression of FADS1 and FADS2 (i.e.
Δ5- and Δ6-desaturases) limiting the synthesis of doco-
sahexaenoic acid and arachidonic acid (Figs. 8 and 9).
The late intermediers of both biochemical pathways e.g.
formation of tetraenoic, pentaenoic and hexaenoic acids
were less pronounced than the very early intermediates.
These changes in the PUFA profile in the liver and in
the serum can be explained by the substrate accumulation
caused by decreased expression of FADSs. n-3 PUFA are
able to coordinate an upregulation of lipid oxidation and a
downregulation of lipid synthesis, thus n-3 PUFA depletion
leads to important metabolic alterations in the murine liver.
Moreover, hepatic steatosis can also occur through a mech-
anism independent of the shift between β-oxidation and
lipogenesis [58]. In Pachikian’s work a slight increase in
total cholesterol was observed in low n-3 mice confirming
the strong relation between n-3 PUFA and cholesterol me-
tabolism [59]. Cellular enrichment of ≥20 PUFAs beyond
the rate-limiting FADS2 enzyme are equally effective in
preventing atherosclerosis and hepatosteatosis [60].
Nevertheless, the precise physiologic and pathologic
role of the hepatic fatty acid alterations observed in our
model of isolated hypercholesterolemia need to be further
investigated in future studies. Moreover, testing the poten-
tial beneficial effects of traditional drugs (e.g. statins), nutra-
ceuticals and functional foods (e.g. resveratrol, plant sterols
and fish oil) on isolated hypercholesterolemia induced liver
steatosis could be a future direction [61]. Moreover, al-
though isolated hypercholesterolemia did not cause any
significant morphological or biochemical alterations indi-
cating steatosis in the pancreas in our study, the unlikely
possibility that isolated hypercholesterolemia may still mod-
ify pancreatic fatty acid composition, cannot be excluded.
Conclusions
In summary, isolated hypercholesterolemia is a well-
established clinical entity affecting approximately 20%
of the hyperlipidemic population. Despite its pronounced
relevance, with the exception of this study, investigations
have not focused on this topic. The present study revealed
that isolated hypercholesterolemia increases the cholesterol
and triglyceride content and influences the fatty acid profile
of the liver without affecting the pancreas. Altered PUFA
synthesis may be explained by the increased hepatic expres-
sion of SCD1 and the decreased hepatic expression of
FADS1 and FADS2. These findings may indicate that iso-
lated hypercholesterolemia is responsible for the early steps
of fat accumulation in the liver. Therefore, fatty acid targeted
therapies with pharmacological tools could presumably form
the basis of a new strategy in treating or preventing steatosis
induced by isolated hypercholesterolemia.
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